Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rick, I do believe they have news of some type coming, but at this point I think the market/investors are treating the company appropriately with in the pps.
If you think about it, if you told your boss you would have the report to them by XX days, and that time comes along and then you tell them it will be another xx days before you can have it to them. Time goes by, nothing has happened, you do not say anything to them about why they do not have it or when it may be coming. I think most people would be leary of what is happening, if anything at all and if you really have been working on the report as you were suppose to. With that occurring and nothing happening then you are probably going to be in a world of hurt with your boss.
Hence how I feel what is happening with POSC pps lately. I think that the MMs and investors are not happy in first being told you will have it on May 5th. Then when that time comes along you are then being told in a couple of weeks to a month or so. Again that time has come and gone, and no word what so ever. So as normal you get in a world of hurt and I think the MMs and investors are reflecting that back to the company. Going from say .25 to .09. It should have sent Positron a good signal and I am concerned they are only making it worse in not contacting their investors to let them know what is happening and to be expected.
Again I am not unloading here. It could go all the way to .00 and I am still holding. I just feel bad for them that they are not following through with their commitments as stated to the media and investors.
This is my last post possible today since I am not a paying member anymore. Sorry I am not able to respond to anything else, but then again you guys may like it that I do not speak. I only share to give my thoughts, feelings on how the company/stock is going in my opinion. Not trying to bash if I am making some strong comments about them, just trying to give out other thoughts to think about.
The Cardio-Assist has been around since 2008.
Here is their latest document from 2009 that is shown on the link you provided.
2009CardioAssistFlyer.pdf
And here is their document from 2008.
2008CardioAssist.pdf
Yes I could tell it wasn't you, Rick.
I just do not understand why this site would not want that information known to the members on this board.
This board stated it would go to $1.00 and past on the news, some saying as high as $2 or $3. I just do not see that happening, especially where we are now. If the pps was higher than it is now and news came out, then yes I could see it going from .20 or so to $1.00. I welcome it, but do not see it happening on a partnership news at this point and pps as of today.
In reply to the PM, .05 should be a good price to get in if it gets that low. I do not see it hitting that lowe this week, but more so next week if nothing is heard by Monday morning. But with the large drop from .12 to sub .09 in the last 3 days, I could see it getting to .06/.07.
Why would an admin here remove my POSC postings over the last 3 days showing the links, data and evidence of POSC's Rooney being ok here? They said it was off-topic and not POSC related. When would facts of the executives not be relavent?
I remember they said the chart was showing that it was going to hit .17 that Thursday, I was hoping they were right and I was wrong about the charts.
As I said before I do not feel charts can predict the future, or tell when news will be coming out on a stock. It can tell you about the past and how the investors reacted to events or news.
News reports ran this up with investors and MMs. And in my opinion, as I have mentioned through last week and I maybe the week before, if no follow through (which is past in my opinion) with the company or it's "inked" partner, then this stock will be hammered hard for lack of doing it or keeping the market informed of it's status.
Now that we are sub .10, even if news came out now, I do not see this getting to over $1.
I am not trying to bash this company, just telling you how I am seeing this playing out and if it survives on lack of news.
With still lack of news, I expect this to continue to sell off hard. Surely seeing sub .09 and possibly falling into the .07xx range to or by end of week as I mentioned last week.
GLTA
Sorry I do not have private messaging anymore.
I am holding long and strong through the end of this year, watching this run up as much as possible. After that I have to pull some funds out to keep food on the table and roof over our heads. Unfortunately I am maxed out in my retirement account to acquire more.
Down about 25% in 3 days, hoping a_blip.
From .12 down to .09 in 3 days. This is taking a real beating lately. I knew this was coming in what I mentioned earlier.
I am not sure where the others folks are at, but I am down about 45%+ on my investment. Or another way to look at it, I need to see a almost a 90% rise to get back to my original investment.
Still holding 220k, but hard to see over $200 loss for every $.001 drop in these very low prices.
I am not selling at these prices as if I do, then I am losing out on everything.
Hoping for that good news soon. Nothinig else to do but wait.
Lantheus Medical Imaging, Inc. Presents Preliminary Data on Novel PET Myocardial
Perfusion Imaging Agent Protocol at SNM Annual Meeting
(Taken from my E*Trade news for POSC)
Flurpiridaz F 18 Data Determine Parameters for One-Day Rest-Stress Test to Detect
Coronary Artery Disease
NORTH BILLERICA, Mass., Jun 09, 2010 (BUSINESS WIRE) -- Lantheus Medical Imaging,
Inc., a worldwide leader in diagnostic medical imaging, today announced
preliminary Phase 2 data describing the methodology used to define an imaging
protocol for a one-day rest-stress myocardial perfusion imaging test using its
novel investigational PET imaging agent flurpiridaz F 18 injection (formerly
known as BMS747158). Flurpiridaz F 18 injection is in development for use with
Positron Emission Tomography (PET) for myocardial perfusion imaging (MPI) to
detect coronary artery disease. Data suggest that the uptake properties of
flurpiridaz F 18 injection make it possible to allow for a relatively low dosing
ratio and a delay of between 30 minutes and one hour between rest and stress
injections, depending on the mode of stress used.
Lantheus, together with its partner in this method development, Cardiovascular
Imaging Technologies of Kansas City, Mo., developed an innovative technique to
determine the dependence of the rest-to-stress dosing ratio in order to identify
the minimum delay between the two injections for a one-day rest-stress test. The
data were featured today in an oral presentation (# 798451) by Joel Lazewatsky,
Ph.D., Principal Research Scientist, Lantheus Medical Imaging, Inc., and in a
poster presentation (# 799099) on Tuesday, June 8 by James A. Case, Ph.D.,
Director of Physics at Cardiovascular Imaging Technologies, at the SNM 57th
Annual Meeting in Salt Lake City.
"Our team used data derived from a Phase 2 clinical study of flurpiridaz F18
injection PET MPI to define the optimal delay between rest and stress dosing as
part of an effort to determine the lowest total dose needed to obtain good
quality images," said Dr. Lazewatsky. "We are currently validating this model
with the second cohort of patients from the Phase 2 clinical study and we look
forward to the results."
To identify the appropriate amounts of rest and stress dosing for hypothetical
same-day rest and stress dosing, computer simulations of same-day rest and stress
images were developed using actual rest and stress image data obtained from 20
patients who were each imaged on a two-day basis. The actual rest and stress
images from the separate days together with the computer simulations of same-day
images were each reviewed in a blinded fashion by three experienced readers.
In evaluating the maximum residual contribution of the imaging agent initially
used in the rest study to the subsequent stress image which did not produce a
meaningful change in the reader's perception of the stress image, it was
determined for stress induced by adenosine (a pharmacological stress agent) that
a minimum dosing ratio of 2.0 (twice as much imaging agent used in stress as
compared to rest) was required with a 30 minute delay between injections. For
stress induced by exercise, a minimum dosing ration of 3.0 (three times as much
imaging agent used in stress as compared to rest) was needed with a one hour
delay between injections.
"Using this novel approach, we expect to validate a protocol that fits into
current clinical practice and that can be administered at the lowest possible
dose for patients undergoing a same-day rest-stress test with flurpiridaz F 18
injection," said Dana Washburn, M.D., Vice President, Clinical Development and
Medical Affairs, Lantheus Medical Imaging, Inc. "We developed this novel
methodology to define the rest and stress doses as well as the optimal delay
between the two doses without having to involve a large number of patients."
Drs. Lazewatsky and Case led the collaboration between Lantheus and
Cardiovascular Imaging Technologies to develop this unique approach to protocol
optimization. "This novel approach of modeling different dosages and time
intervals based on baseline image data not only enabled recognition of optimal
acquisition parameters for image quality and dosimetry, but dramatically
shortened development time that otherwise would have depended on trial and error
methodology," said Dr. Case.
About Flurpiridaz F 18 Injection
Flurpiridaz F 18 injection, a fluorine 18-labeled agent that binds to
mitochondrial complex 1 (MC-1), was designed to be a novel myocardial perfusion
PET imaging agent for the diagnosis of coronary artery disease (CAD). The agent
is currently in Phase 2 clinical development. CAD is the leading cause of death
in the United States for both men and women(1). Each year, more than half a
million Americans die from CAD(1).
In Phase 1 clinical studies, flurpiridaz F 18 injection was well-tolerated and
demonstrated radiation dosimetry that suggests that good quality images may be
obtained with patient radiation doses that are within accepted limits. The data
also showed high myocardial uptake at rest that significantly increased with
pharmacologically induced stress as well as a ratio of myocardial to background
uptake that was favorable and improved over time, suggesting encouraging
potential as a myocardial perfusion PET imaging agent for patients both at rest
and under stress.
About PET and MPI
Positron emission tomography, also called PET imaging or a PET scan, is a type of
nuclear medicine imaging procedure(2) that provides information about the
function and metabolism of the body's organs, unlike computed tomography (CT) or
magnetic resonance imaging (MRI), which primarily show anatomy and structure(3).
Myocardial perfusion imaging (MPI) is a non-invasive test that utilizes a small
amount of radioactive material (radiopharmaceutical) injected into the body to
depict the distribution of blood flow to the heart(4). MPI is used to identify
areas of reduced blood flow (perfusion) to the heart muscle(4). The test is
typically conducted under both rest and stress conditions, after which physicians
examine and compare the two scans and predict whether the patient has significant
coronary artery disease(4). Although single-photon emission computer tomography
(SPECT) is most commonly used for MPI(5),PET imaging has gained considerable
support and use in the field of cardiovascular imaging, as it offers many
advantages to SPECT, including higher spatial and contrast resolution, which
results in higher image quality and improved diagnostic accuracy, accurate
attenuation correction and risk stratification(6).
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for
more than 50 years, is dedicated to creating and providing pioneering medical
imaging solutions to improve the treatment of human disease. The company's proven
success in discovering, developing and marketing innovative medical imaging
agents provides a strong platform from which to bring forward breakthrough new
tools for the diagnosis and management of disease. Lantheus imaging products
include the echocardiography contrast agent DEFINITY(R) Vial for (Perflutren
Lipid Microsphere) Injectable Suspension, ABLAVAR(R) (gadofosveset trisodium), a
first-in-class magnetic resonance agent indicated for the evaluation of
aortoiliac occlusive disease in adults with known or suspected peripheral
vascular disease, TechneLite(R) (Technetium Tc99m Generator), Cardiolite(R) (Kit
for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium
201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 600 employees
worldwide with headquarters in North Billerica, Massachusetts, and offices in
Puerto Rico, Canada and Australia. For more information, visit
http://www.lantheus.com.
About Cardiovascular Imaging Technologies, LLC.
Cardiovascular Imaging Technologies, LLC. is based in Kansas City, Missouri.
CVIT's business interests include development of cardiac imaging software, core
imaging lab functions, new-agent consulting, technical support services, and
research support for Phases 1 through 4 investigations. Its core lab specializes
in modeling early Phase 1 and Phase 2 studies to help design more scientific and
accurate later stage clinical trials. The core lab also specializes in site
training and quality maintenance during later phase studies to insure data
consistency across a broad range of investigator instrumentation. It is a
recognized pioneer in the evolution of myocardial perfusion PET. Its processing,
quality control, and myocardial perfusion quantitation software is used by more
than 50% of PET centers that regularly perform myocardial perfusion imaging.
(1) National Institutes of Health, National Heart, Lung, and Blood Institute.
Coronary Artery Disease: Who Is At Risk.
http://www.nhlbi.nih.gov/health/dci/Diseases/Cad/CAD_WhoIsAtRisk.html
(http://www.nhlbi.nih.gov/health/dci/Diseases/Cad/CAD%5fWhoIsAtRisk.html).
Accessed on June 4, 2010.
(2) Radiology Info. What is Positron Emission Tomography -- Computed Tomography
(PET/CT) Scanning. http://www.radiologyinfo.org/en/info.cfm?pg=PET. Accessed on
June 4, 2010.
(3) National Institutes of Health. NIH Clinical Center. Positron Emission
Tomography Department Overview. http://clinicalcenter.nih.gov/pet/. Accessed on
June 4, 2010.
(4) Society of Nuclear Medicine. Procedure Guidelines for Myocardial Perfusion
Imaging. Version 3.0 June 2002. http://interactive.snm.org/docs/pg_ch02_0403.pdf
(http://interactive.snm.org/docs/pg%5fch02%5f0403.pdf).
(5) Salerno, M and Beller, GA, Noninvasive Assessment of Myocardial Perfusion.
Circ Cardiovasc Imaging. 2009; 2:412-424.
(6) Heller, G, Calnon, D and Dorbala, S. Recent Advances in Cardiac PET and
PET/CT Myocardial Perfusion Imaging. J Nucl Cardiol 2009; 16:962-9.
SOURCE: Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc.
Priscilla Harlan, 978-671-8854
Cell: 781-799-7917
or
Pure Communications, Inc.
Michele Rozen, 617-730-8284
Cell: 617-953-2214
Copyright Business Wire 2010
We just broke below .10 on both sides.
The highest Bid Price is not reflected on this site.
UBSS is reflecting .0965, but there are other MMs reflecting higher bids.
And if they are going just by UBSS, then the Ask price should be reflecting .12. Something is messed up on this site on the pricing it seems to me.
captttam, Yes they have but I can not blame them for how the company has been reporting what will be happening and when. Almost like a parent scolding a child in my opinion.
$.001 of $.10 is 1%, it makes sense, though I hate seeing it look negative like that.
Which explains why this stock can gain or lose so much so fast compared to the NYSE, where $100 of $10000 is 1%.
HGS, I think in order to attract purely new investors, those that do not currently or previously owned this stock, is to have that news we all have been waiting for to come out. I thinking hold .10 is a must in order to help others get in, or back in, but without that news we will not move upwards.
Let's hope that we do not break below .10 today in trading and it can held with the MMs.
Interesting way to start the day. 323 shares @ .10
Darn, I thought maybe new news and partnership or buyout were being reported.
roelien, You did not state anything about the posting so I first thought it was new news, but then I saw it was 2 years old. Did you mean to post something from today, or did you mean to post this old article?
OK, need clarification.
PharmAssist is here?
Sold - the company?
Medaxiom the new partner?
If the distribution continues into tomorrow, then we should see sub .10 as todays trading was almost 1 buy to every 4 sold.
I hope it runs tomorrow as I will not be around to see what happens for part of the day.
Still staying positive on this stock. Just feeling like the fire is getting a little hotter than I thought it would be.
I hope tomorrow brings the news we all have been waiting for on the partnership. I think at this point if it is not big news which everyone is expecting, then the investors will sell this off big time.
Looking over the last 30 days of trading, I see that this stock has been in a distribution mode since April 30 with maybe a few days of accumulation.
Accumulation peeked on April 29th.
These past two days show a large increase in Distribution, with the last small accumulation occurring on May 17th.
Come on Positron, put some good news out on the Business Wire.
1(buy) to 3.5(sells) trading now.
Either we are going to see this soar, or pop like a pimple.
Our daily volume is increasing into the 2M, up from the pre 1M we had before if I remember correctly.
At least for now we are holding onto .10.
If we keep falling, I do not see us even being able to get anywhere close pps wise to the company POSC was being compared to on this board. I fear unless Positron, or the partner(s), is to release something, we may see .07-.08 and if we do have news then, I only see this maybe going up to .25-.35 by the time any news (if it does) come out this month. If the news came at when it was originally stated, then I could have seen this run up to possibly $1 or more.
I am still hopeful. Hopefully this is accumulation going on today and yesterday. Maybe the buying will pick up. Maybe we can get Rooney to have the company release new news to let everyone know what is happening, as I think investors, and not just myself, are concerned for the company and it's future.
1to3 Trading. Either large accumulation or sell off occurring to me, at least how I am looking at it.
Buy to Sell Volume is about 1 to 3.
Buy Vol 377,205
Sell Vol 1,151,045
Unk Vol 221,390
Either MMs or someone is trying to accumulate, or a sell off is occuring. I have not see numbers tilted this much before on here, but maybe some of you have. I wish I could tell. Would be easier to tell if we had news out today on Positron about the partnership than it would be easy to tell.
Lantheus Medical Imaging, Inc. Presents Phase 1 Data Highlighting Safety,
Dosimetry and Tolerability of Novel PET Heart Failure Imaging Agent at SNM Annual
Meeting
(Shown as news on E*trade)
N. BILLERICA, Mass., Jun 08, 2010 (BUSINESS WIRE) -- Lantheus Medical Imaging,
Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for
its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI
1195, which is in development for the evaluation of patients at risk of heart
failure or sudden cardiac death. The preliminary data showed that LMI 1195 can
render high-quality, well-defined images of the cardiac autonomic nervous system,
which helps regulate the electrical activity of the heart and its ability to
contract(1). In addition to the high and uniform myocardial uptake, the
radiotracer cleared quickly from the blood and had a favorable safety and
dosimetry profile.
The Phase 1 data were featured in two separate poster presentations at the SNM
57th Annual Meeting in Salt Lake City. Data examining the myocardial uptake of
LMI 1195 were presented by Yi-Hwa Liu, Ph.D., Associate Professor of Medicine
(Cardiology), Yale School of Medicine on Monday, June 7 (poster #798819), and
radiation dosimetry data are being presented by Joel Lazewatsky, Ph.D., Principal
Research Scientist, Lantheus Medical Imaging, Inc., today, Tuesday, June 8
(poster #797609).
"There has been limited understanding to date of the functioning of the heart's
autonomic nervous system through imaging," said L. Veronica Lee, M.D., Medical
Director at Lantheus Medical Imaging. "The data from this Phase 1 study of LMI
1195 demonstrating safety and tolerability in healthy subjects are encouraging,
as we prepare to initiate Phase 2 clinical trials later this year. Although
preliminary, these data suggest that PET imaging with LMI 1195 has the potential
to provide physicians with a clear view of the autonomic nervous system of the
heart, which would be helpful for the identification and evaluation of heart
failure patients. They also suggest that physicians may be able to view specific
regions of the heart, which could potentially facilitate diagnosis and evaluation
of heart failure."
The Phase 1 study was an open-label, non-randomized, single-dose study designed
to estimate the radiation dosimetry of LMI 1195 in healthy subjects undergoing a
PET scan, to evaluate the safety and tolerability of the tracer, and to assess
PET imaging parameters and image quality. Twelve healthy subjects received a
single intravenous (IV) bolus injection of 150-250 megabecquerel (MBq) of LMI
1195. Dynamic PET images were obtained of the heart for 10 minutes, followed by
sequential whole body images for approximately five hours. Blood samples were
obtained and heart rate, electrocardiogram and blood pressure were monitored
prior to and during imaging. Residence times were determined from
multi-exponential regression of regions of interest (ROI) data normalized by
injected dose. Radiation dose estimates were calculated using Organ Level
INternal Dose Assessment EXponential Modeling (OLINDA/EXM). Myocardial (M), lung,
liver (LI), and blood pool standardizeduptake values were determined at different
time intervals.
The data demonstrated that LMI 1195 yields a radiation dose comparable to that of
other commonly-used PET radiopharmaceuticals, and that good image quality is
possible at the given dose. There were no adverse events associated with LMI 1195
in this study. The four highest-dose organs and their respective mean dose
estimates were urinary bladder wall, 3.5-hour void (0.10 ? 0.020 mSv/MBq),
kidneys (0.083 ? 0.014 mSv/MBq), thyroid (0.066 ? 0.011 mSv/MBq) and small
intestine (0.046 ? 0.008 mSv/MBq). Mean effective dose was 0.026 ? 0.0012
mSv/MBq. Approximately 1.6 percent of the injected dose (ID) was seen in the
myocardium initially, remaining above 1.5 percent of ID (decay-corrected) through
four hours after injection. M/LI ratio was initially approximately equal
increasing to more than two at four hours. Blood radioactivity cleared quickly
and lung activity was low throughout the study.
The findings were augmented by preliminary results observed in six healthy
subjects at a single clinical trial site that showed that LMI 1195 cleared
quickly from the blood and demonstrated a favorable biodistribution for early
cardiac imaging. Regional and global myocardial activity peaked within the first
10 minutes and reached a plateau at approximately 60 minutes post injection.
Attenuation corrected images were reoriented into standard cardiac specific axes,
and the maximal regional myocardial uptake was quantified on a sector-by-sector
basis. The heart images were divided into three short axis slices and four radial
sectors, and mean regional uptake for each sector was calculated. Activity was
expressed as Bq/ml. There was no significant variation (p=0.69, ANalysis Of
Variance (ANOVA)) in regional myocardial uptake at this time around the
circumference of the heart. There was also no significant (p=0.08, ANOVA)
base-to-apex gradient in myocardial uptake.
"We believe that PET imaging with LMI 1195 has the potential to change how heart
failure patients are evaluated," added Dana Washburn, M.D., Vice President,
Clinical Development and Medical Affairs, Lantheus Medical Imaging, Inc.
"Lantheus is committed to advancing our PET imaging pipeline because of the power
of PET technology to further improve cardiac imaging."
About LMI1195 and Heart Failure
LMI 1195 is a novel F-18 tracer designed to use positron emission tomography to
improve imaging of cardiac neuronal function. LMI 1195 has completed Phase 1
clinical trials. In preclinical studies, LMI 1195 showed promise as a heart
failure imaging agent with high cardiac sympathetic nervous system uptake.
About Heart Failure
Heart failure is a serious medical condition, in which the heart muscle
progressively loses its ability to pump blood, that affects more than five
million people in the United States and results in about 1.1 million
hospitalizations and 300,000 deaths each year(2,3).Patients with heart failure
are six to nine times more likely than the general population(4) to suffer sudden
cardiac death as a result of abnormal cardiac neuronal function resulting in a
fatal arrhythmia. According to the American Heart Association, the total cost of
heart failure is estimated to be $37.2 billion in 2009, putting significant
health and financial burdens on patients, their families and society as a whole.
Currently, diagnosing heart failure is based on presenting symptoms, patient
self-reports, physical exams, tests and a patient's medical history, none of
which focus on actual cardiac neuronal function.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for
more than 50 years, is dedicated to creating and providing pioneering medical
imaging solutions to improve the treatment of human disease. The company's proven
success in discovering, developing and marketing innovative medical imaging
agents provides a strong platform from which to bring forward breakthrough new
tools for the diagnosis and management of disease. Lantheus imaging products
include the echocardiography contrast agent DEFINITY(R) Vial for (Perflutren
Lipid Microsphere) Injectable Suspension, ABLAVAR(R) (gadofosveset trisodium), a
first-in-class magnetic resonance agent indicated for the evaluation of
aortoiliac occlusive disease in adults with known or suspected peripheral
vascular disease, TechneLite(R) (Technetium Tc99m Generator), Cardiolite(R) (Kit
for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium
201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 600 employees
worldwide with headquarters in North Billerica, Massachusetts, and offices in
Puerto Rico, Canada and Australia. For more information, visit
http://www.lantheus.com.
(1) American Heart Association. Autonomic Nervous System.
http://www.americanheart.org/presenter.jhtml?identifier=4463. Accessed on May 27,
2010.
(2) National Heart Lung and Blood Institute. What is Heart Failure?
http://www.nhlbi.nih.gov/health/dci/Diseases/Hf/HF_WhatIs.html
(http://www.nhlbi.nih.gov/health/dci/Diseases/Hf/HF%5fWhatIs.html). Accessed on
May 27, 2010.
(3) American Heart Association. News Release: Updated Heart Failure Guidelines
Focus on Key Research Findings, Clinical Advances.
http://www.newsroom.heart.org/index.php?s=43&item=699. Accessed on May 27, 2010.
(4) American Heart Association. Heart Disease and Stroke Statistics, 2009 Update.
http://www.americanheart.org/downloadable/heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009.pdf.
Accessed on May 27, 2010.
SOURCE: Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc.
Priscilla Harlan, 978-671-8854, Cell: 781-799-7917
or
Pure Communications, Inc.
Michele Rozen, 617-730-8284, Cell: 617-953-2214
Copyright Business Wire 2010
I think Personal Attack is very subjective.
One could take it as a personal attack as in being sworn at, as in being told to leave, as in being yelled at (caps), etc etc etc.
It is all upon who is reading it and how they take it.
I have seen what I call extreme personal attacks on here and nothing happened to them at all. Very subjective for sure.
David, I have seen tons of those so called news reports, but actually they are an advertisement asking you to join their service.
We are back at .10, will be interesting to see if investors (MM and all) will make a hold in the sand here as before, or if it will be allowed to fall more wondering when Positron will bring out the news on orders and partnership.
So far equal buying and selling at this point.
You may be able to find some information under Settings and then My Removed Posts. It may give you a possible clue if they said anything.
Update dblue & JJ
This is my 15th post of the day so I can not do any more today so combining these together.
dblue, is this something Rooney stated at the SNM conference, as I was not able to listen to it? Or from his comments last month with the partnership and it growning each year over the next 5 years, and I think he said substantially each year?
JJ, I checked out the site and their meaning. The information looked at is not if the the trade was executed on the Bid or Ask side. It only looks at the current price and last price that it traded at. In itself could also be useful. Thanks!
Up Volume - is the total volume for all trades during the day where the trade was done at a higher price than the previous trade
Neutral Volume - is the total volume for all trades during the day where the trade was done at the same price as the previous trade.
Down Volume - is the total volume for all trades during the day where the trade was done at a lower price than the previous trade.
JJ, I am not sure where you are getting your numbers, but I am looking at them on here in the trade section. Can you tell me where you are getting your break down trade numbers from? I would like to figure out the discreptency.
Here is what this site is showing. If you want to know more in detail you would need access to the link on the site screen above.
Buy Vol 622,282 (people buying into the Ask price)
Sell Vol 1,138,394 (people selling into the Bid price)
Unk Vol 265,200 (trades where the price was someone between the bid and Ask price)
Buying/Selling Volume now at about 6/11.
Every 6 shares are being bought at the Asking price, 11 shares being sold into the Buy price.
Buying/Selling Volume today about 5/8.
That is to say for about every 5 shares are being bought at the Asking price, 8 shares being sold into the Buy price.
Today's Short Information
This is today's short information up through this time. How accurate it is I am not really sure as I just signed up on this site yesterday and have not had any way to validate it, but I still wanted to share it with you.
If the volume is correct, then we are looking at almost 1/3 the total volume and over 1/2 the chunk in the sell volume (I am assuming that is where it would be placed at if they are selling/shorting).
Acquired from BUYINS.net
Intraday SqueezeTrigger
Symbol: POSC
Short Volume Today: 479,381 shares
Intraday SqueezeTrigger Price: $0.11
Buying/Selling Volume today about 5/8.
That is to say for about every 5 shares are being bought at the Asking price, 8 shares being sold into the Buy price.
Is this available for Verizon?
Rick, I completely agree, and would not be surprised even higher. I do not understand why they do not put themselves out there more. Just because they say they can not announce the new partner(s), does not mean they have to be quiet.
I am really suprised on the lack of follow up as well.
I thought you were asking me since you replied to my post and not to ihategeeks post.
Rick, ihategeeks posted the conference information.
Here is a link to his posting.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50975348
ihategeeks, I am not trying to be negative more than I am trying to be realistic in how these play out when a company states that news will be out in xx time, and when it is not, the company usually sees a fell off in it not occurring. More of investors (MMs or individuals) punishing the company for what did not happen as was stated.
Is this news conference on POSC information? Or just general things going on?
We have now reached, if not exceed, two weeks to a month or so in what was announced in the MarketSite for the breaking news on the $25B company partnership. With that time now lapsed and no news from Positron or the NYSE Partner, I think we are going to see the sub .10 if not today then a little later this week.
Investors expect follow through on what is said no matter who the company is. If it does not happen, then you usually see the investors selling off to avoid a possible rush later on.
I am not trying to bash this company, just stating how I feel this will play out this week if Positron does not release the informaiton today or tomorrow. I hope I am wrong, but do not be surprised if we see sub .10 and from there look for .07 in my opinion.
Again I am still long on 220k shares.